Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Concomitant Exacerbation of Graves Orbitopathy and Double-Seronegative Myasthenia Gravis after SARS-CoV-2 Infection.
JCEM Case Rep
February 2025
First Department of Internal Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.
SARS-CoV-2 infection could trigger autoimmune disease. We report a case of concomitant exacerbation of Graves orbitopathy (GO) and myasthenia gravis (MG) after SARS-CoV-2 infection. A 43-year-old woman had diplopia, proptosis, and swollen eyelids.
View Article and Find Full Text PDFImmunotherapy Responsive Recurrent Post-Infectious Ataxia Associated With Recurrent Gene Variant.
Neurol Genet
February 2025
Division of Neurology, Department of Pediatrics, Children's Hospital Los Angeles, CA; and.
Objectives: We detail a case of recurrent, postinfectious, cerebellar ataxia associated with a likely pathogenic previously documented gene variant in .
Methods: The patient was identified after her second hospitalization for postinfectious cerebellar ataxia. Genetic testing was performed after discharge.
CMAP prediction and experimental validation of Forskolin as a podocyte protective and anti-proteinuric drug for nephrotoxic serum-treated mice.
Biochem Pharmacol
December 2024
The National Clinical Research Center for Kidney Diseases, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China; The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China. Electronic address:
Podocyte injury leads to proteinuria and glomerular diseases. Different podocyte injuries have distinct mechanisms. It is desirable to use a regimen that targets the mechanism of a given podocyte injury for a specific and improved result.
View Article and Find Full Text PDFClinical performance of a novel and rapid bioassay for detection of thyroid-stimulating immunoglobulins in Graves' orbitopathy patients: a comparison with two commonly used immunoassays.
Front Endocrinol (Lausanne)
October 2024
Laboratory Medical Immunology, Department of Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands.
Background: For the selective detection of thyroid-stimulating hormone receptor antibodies with stimulating properties (thyroid-stimulating immunoglobulins; TSI), a novel and rapid bioassay (Turbo TSI) has been introduced. We evaluate the clinical performance of Turbo TSI in Graves' orbitopathy (GO) patients and compare it to a bridge-based TSI binding immunoassay and third generation TSH-R-binding inhibitory immunoglobulins (TBII) assay. Also, we investigate the association of Turbo TSI and TBII measurements with GO activity and severity, as well as response to intravenous methylprednisolone (IVMP), and compare results to previous findings on the bridge-based TSI binding immunoassay.
View Article and Find Full Text PDFLong-term outcome of Graves' orbitopathy following treatment with sirolimus.
J Endocrinol Invest
October 2024
Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
Article Synopsis
- Sirolimus was found to help people with Graves' orbitopathy (a condition that affects the eyes) more than another medicine called methylprednisolone at the 24-week mark.
- In the study, 40 patients were treated, and researchers looked at how they felt and their eye symptoms over 48 weeks.
- While sirolimus showed better results at 24 weeks, both medicines had similar outcomes at 48 weeks, suggesting that longer treatment might be needed for better results.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!